Related Experiment Videos
Long-term strategies for peptic ulcer
1GE Unit, Monash Medical Centre, Clayton, Victoria, Australia.
Scandinavian Journal of Gastroenterology. Supplement
|January 1, 1995
Summary
Most peptic ulcers recur after stopping treatment. Continuous H2-receptor antagonist therapy effectively prevents recurrence in high-risk patients, though Helicobacter pylori eradication offers a potential permanent cure.
Area of Science:
- Gastroenterology
- Pharmacology
Background:
- Peptic ulcer recurrence is common after treatment cessation.
- Long-term H2-receptor antagonist therapy is a standard approach for preventing relapse in at-risk individuals.
Purpose of the Study:
- To review the efficacy and indications for long-term H2-receptor antagonist therapy in peptic ulcer management.
- To discuss the potential impact of Helicobacter pylori eradication on long-term treatment strategies.
Main Methods:
- Literature review of studies on peptic ulcer recurrence and management.
- Analysis of patient subgroups benefiting from continuous versus intermittent H2-antagonist therapy.
- Consideration of Helicobacter pylori eradication as a curative option.
Main Results:
- Continuous H2-antagonist therapy is effective in preventing recurrence, especially in elderly patients, those on NSAIDs, or with prior complications.
- Intermittent therapy may be suitable for younger patients without complications or comorbidities.
- H2-antagonists demonstrate a favorable safety profile and cost-effectiveness.
Conclusions:
- Long-term H2-receptor antagonist therapy remains a valuable tool for managing peptic ulcer recurrence in specific patient groups.
- Helicobacter pylori eradication presents a promising alternative for achieving a permanent cure, potentially reducing the need for long-term medication.